Cullinan Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cullinan Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Cullinan Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$40.6M, a 3.51% decline year-over-year.
  • Cullinan Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$144M, a 8.07% increase year-over-year.
  • Cullinan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$153M, a 238% decline from 2022.
  • Cullinan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $111M.
  • Cullinan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$65.6M, a 26.6% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$144M -$40.6M -$1.38M -3.51% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$142M -$42M -$9.81M -30.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$132M -$37.1M +$20.8M +35.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$153M -$23.8M +$2.98M +11.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 -$156M -$39.2M -$14.4M -58% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$142M -$32.2M -$207M -118% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $65.4M -$58M -$45.9M -379% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $111M -$26.8M +$5.73M +17.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $105M -$24.8M -$7.45M -43% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $113M $175M +$191M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$77.6M -$12.1M -$12M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$65.6M -$32.5M -$4.17M -14.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$61.4M -$17.4M -$7.49M -76% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$53.9M -$15.6M -$7.01M -81.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$46.9M -$70K* +$4.9M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$51.8M -$28.3M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$9.86M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$8.62M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$4.97M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.